Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
70 participants
INTERVENTIONAL
2025-05-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Does the use of the Alesis OSA-1 device reduce the number of AHI events after six treatments of 12 minutes each, 2x per week x 3 weeks, in adult OSA patients?
Researchers will compare results of 35 control group participants who will not receive treatment to a treatment group who will receive six, 12 minute, non-invasive low laser light therapy (LLLT) treatments, two per week for 3 weeks, to see if there is a reduction in the number of AHI events and size of redundant and soft tissues in adult OSA patients.
Participants will:
* Visit the clinic for assessment and instructions on using the at home sleep study system, WatchPat, and obtain baseline information
* Use the WatchPat system to record AHI events pre- and post-treatment.
* 10 randomly selected participants will receive a pre-study pulmonary functions test (PFT) and repeated post-treatment.
* 5 randomly selected participant will receive a pre-study MRI of the head/neck and repeated post treatment.
* For the treatments, the participant lie on a treatment table under a LLLT device for 12 minutes, two times per week, x 3 weeks.
* Be offered the treatment series at the conclusion of the study if they were selected for the control group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phototherapy for Non-responders to Oral Appliance Therapy for Obstructive Sleep Apnea
NCT06960200
Bright Light Therapy for OSA
NCT05917119
Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea
NCT04299009
eXciteOSA for Treatment of Mild Obstructive Sleep Apnea
NCT05183009
Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea
NCT06008626
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES
* To evaluate changes in the size of the tongue and soft tissue structures in obese subjects diagnosed with obstructive sleep apnea (OSA).
* To assess improvements in the Apnea-Hypopnea Index (AHI) following treatment with the Alesis Airway LLT Modification Device.
STUDY DESIGN
* Type: Prospective, repeated measures, double blind, randomized controlled trial
* Participants: N = 70 for original study, N = 5-10 MRI subset, N = 35 for ethical consideration offering (See Ethics considerations)
* Sampling Method: Volunteer convenience sample
* Duration: 6 months
* Special subset A: A subset of 3-10 participants will undergo a MRI evaluation to measure submental and tongue fat size, pre- and post-treatment (Reference: Schwab, et al. 2014, Tongue fat and OSA relationship)
* Repeated Measures: Post-Treatment HST week 2, week 3
PARTICIPANTS Inclusion Criteria
* Suspicion of OSA
* STOP BANG score of 3 or greater (See STOP BANG CRITERIA)
* Age ≥ 18 years - 70
* Obese (BMI ≥ 25) Exclusion Criteria
* Beards - beard
* Central Sleep Apnea
* Inability to hold mouth open 12 minutes
* Age \> 75/ \< 18
* Severe comorbid conditions that may affect treatment or inability to lie flat or sit for 20 minutes (e.g., severe cardiac disease, uncontrolled diabetes)
* Contraindications to MRI (e.g., non-MRI-compatible pacemakers).
* History of recent upper airway surgery.
* Active cancer or cancer treatment completion within 1 year
DEMOGRAPHICS \& COMORBIDITIES
* Demographics
* Participants Identifier Number
* Age•
* Sex
* Height
* Weight
* BMI
* Significant Comorbidities (e.g., diabetes, hypertension, cardiac disease, kidney disease, memory issues, narcolepsy)
* Comorbidities: Although not exclusion criteria, document significant medical history, including:
* Diabetes
* Hypertension
* Cardiac disease
* Kidney disease
* Memory loss or cognitive issues
* Narcolepsy
* Other relevant conditions
* Medication use contraindicated on consent
TREATMENT PROTOCOL \& INTERVENTION
* Device: Alesis OSA-1
* Pre-Admission Steps
* Basic health history
* Qualitative survey for participants for anecdotal data and quotes
* STOP BANG assessment (Score of ≥ 3 )
* Consent to treat and Informed consent for study participation
* Pre-Treatment Steps
* Randomization into treatment and control groups using alternative numbering system
* Baseline height and weight
* Baseline physical measurements per tape measure on neck circumference included in the STOP BANG
* Baseline AHI Study using WatchPat device
* 3D Imaging of treatment area
* SUBSET A: 5 participants will get baseline MRI
* Measure tongue adipose, size, and structure shape
* Measure submental tissue size
* SUBSET B: 10 randomly selected participants will get pre and post
Session Details
* Duration: 12 minutes per treatment session -Facing front with mouth open
* LLLT 5 cm from face/neck
* Goggles for eye protection
* Frequency: 6 sessions over a set period (e.g., 3 weeks), 2 x week x 3 weeks
* Control group will receive light therapy with a sham connector between the control console and light/arm assembly, that operates the cooling fans with the 635nm light off in order to mimic invisible light.
Post-Treatment Steps:
* After the last treatment in week 3: Post treatment AHI test, Weight, STOP BANG score, neck circumference measurement, and qualitative questionnaire 5 questions.
* After week 3 and last week of treatment - 3D Imaging will be completed using the Vector camera system
* Qualitative data survey for participants for anecdotal data and quotes
* SUBSET A: MRI Group - MRI repeated after week 3, session 6.
* SUBSET B: PFT Group - PFTs repeated after last treatment in week 3, session 6.
Ethical Considerations
* To benefit health care and do the ethical thing for society, control group participants will be offered the intervention treatments, post-study, if results demonstrate a reduction in incidence of AHI 20% or greater.
* Control participants (Group A) that opt for the treatments post study, will utilize the home study sleep monitoring and data will be used to compare to data collected during their control group assignment.
TOOL • Home Monitoring: Participants will use the WatchPAT device to monitor AHI prior to study and repeated after 6 treatments.
MEASUREMENTS
* Pre-Treatment Assessment
* AHI Monitoring:
* Use WatchPAT devices for baseline AHI measurement.
* AHI event occurrence per hour
* Respiratory Disturbance Index data: apneas, hypopneas, respiratory effort related arousals (RERAs) per hour of sleep
* Oxygen disturbance Index data: SpO2 % drop data
* SpO2 levels via pulse oximetry: nadir/lowest, average during sleep, thresholds
* Vital signs - Heart rate average, HR variability patterns
* Total sleep time
* Latency - time to fall asleep
* REM latency - time to REM
* Sleep stage data - estimate
* Snoring intensity
* Body position
* Cheyne-stokes respirations for Central Sleep Apnea
* Movement
* Peripheral arterial tone (sympathetic responses and events
* MRI Measurements on 10 randomized participants:
* Post-Treatment Assessment
* AHI Monitoring:
* Repeat AHI measurement with WatchPAT system after the completion of all treatment sessions.
* MRI Measurements on 5-10 randomized participants:
* Repeat MRI to evaluate airway size, volume, and structure/changes
DATA ANALYSIS
* Analysis Methods:
* Compare pre- and post-treatment AHI values using paired t-tests or Wilcoxon signed-rank tests as appropriate.
* Analyze changes in MRI measurements using repeated measures ANOVA or mixed-model analysis.
* Correlation between fat loss and reduction in AHI events, STOP BANG using Pearson's Correlation Coefficient
EXPECTED OUTCOMES
* Identification of correlations between treatments and changes in the volume or tongue and submental tissue volume
* Evaluation of the effectiveness of the Alesis OSA1 treatment in reducing AHI in participants with OSA.
ETHICAL CONSIDERATIONS
* Obtain informed consent from all participants.
* Ensure confidentiality and data protection throughout the study.
* Offer post-treatment procedures to control group participants if results demonstrate 20% or greater reduction in AHI events
CONCLUSION
• This study aims to provide insights into the effects of non-invasive LLLT airway modification treatment on OSA, enhancing understanding of the relationship between soft tissue structures and apnea severity in obese individuals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DEVICE_FEASIBILITY
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alesis OSA-1 Effectivness
The treatment group of the study will receive LLLT from the previously FDA 501(k) class I approved Ultraslim device, now rebranded under the name Alesis OSA-1. N=35 participants will receive non-invasive LLLT at 635nm wavelength for 12 minutes, 2x per week, x 3 weeks.
The Alesis OSA-2 device will be used for this arm of the study.
OSA LLLT treatment device
The Alesis OSA-1 is a LLLT that uses 635nm wavelength to stimulate the mitochondria to open cell spaces and allow oils, lipids, and fluids to drain into the body systems.
MRI Assessment
5 participants from the treatment group will be randomly selected to receive to pre and post magnetic resonance imaging (MRI) on the head/neck to determine change in size or volume of soft tissue and fat within the airway/neck structures.
No interventions assigned to this group
PFT Assessment
Ten participants, 5 from the treatment group and 5 from control, will receive pre and post study pulmonary function testing (PFT) to evaluate changes in pulmonary volumes related the treatments.
No interventions assigned to this group
OSA-1 Control group
A modified device utilizing a pigtail connector to bypass active treatment while allowing the cooling fans to operate for the treatment period, giving the appearance of treatment with invisible light.
Sham Comparator
A modified device utilizing a pigtail connector to bypass active treatment while allowing the cooling fans to operate for the treatment period, giving the appearance of treatment with invisible light.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OSA LLLT treatment device
The Alesis OSA-1 is a LLLT that uses 635nm wavelength to stimulate the mitochondria to open cell spaces and allow oils, lipids, and fluids to drain into the body systems.
Sham Comparator
A modified device utilizing a pigtail connector to bypass active treatment while allowing the cooling fans to operate for the treatment period, giving the appearance of treatment with invisible light.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Photonica USA, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joaquin Hechavarria, MD
Role: PRINCIPAL_INVESTIGATOR
JD Medical Group, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
JD Medical Group, LLC
Miami, Florida, United States
Bioresearch Institute, Llc.
Miramar, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Medical Advisory Secretariat. Polysomnography in patients with obstructive sleep apnea: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(13):1-38. Epub 2006 Jun 1.
Sutherland K, Lowth AB, Antic N, Carney AS, Catcheside PG, Chai-Coetzer CL, Chia M, Hodge JC, Jones A, Kaambwa B, Lewis R, MacKay S, McEvoy RD, Ooi EH, Pinczel AJ, McArdle N, Rees G, Singh B, Stow N, Weaver EM, Woodman RJ, Woods CM, Yeo A, Cistulli PA. Volumetric magnetic resonance imaging analysis of multilevel upper airway surgery effects on pharyngeal structure. Sleep. 2021 Dec 10;44(12):zsab183. doi: 10.1093/sleep/zsab183.
Wang SH, Keenan BT, Wiemken A, Zang Y, Staley B, Sarwer DB, Torigian DA, Williams N, Pack AI, Schwab RJ. Effect of Weight Loss on Upper Airway Anatomy and the Apnea-Hypopnea Index. The Importance of Tongue Fat. Am J Respir Crit Care Med. 2020 Mar 15;201(6):718-727. doi: 10.1164/rccm.201903-0692OC.
Orestes MI, Tuchayi SM, Wang Y, Farinelli W, Arkun K, Anderson RR, Thomas R, Garibyan L. Safety and feasibility of selective tongue fat reduction with injected ice-slurry. Laryngoscope Investig Otolaryngol. 2022 Sep 9;7(5):1675-1680. doi: 10.1002/lio2.902. eCollection 2022 Oct.
Kirsch DB. Obstructive Sleep Apnea. Continuum (Minneap Minn). 2020 Aug;26(4):908-928. doi: 10.1212/CON.0000000000000885.
Guo J, Xiao Y. New Metrics from Polysomnography: Precision Medicine for OSA Interventions. Nat Sci Sleep. 2023 Mar 9;15:69-77. doi: 10.2147/NSS.S400048. eCollection 2023.
Kennedy J, Verne S, Griffith R, Falto-Aizpurua L, Nouri K. Non-invasive subcutaneous fat reduction: a review. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1679-88. doi: 10.1111/jdv.12994. Epub 2015 Feb 9.
Moon IJ, Choi JW, Jung CJ, Kim S, Park E, Won CH. Efficacy and safety of a novel combined 1060-nm and 635-nm laser device for non-invasive reduction of abdominal and submental fat. Lasers Med Sci. 2022 Feb;37(1):505-512. doi: 10.1007/s10103-021-03288-z. Epub 2021 Apr 2.
Caruso-Davis MK, Guillot TS, Podichetty VK, Mashtalir N, Dhurandhar NV, Dubuisson O, Yu Y, Greenway FL. Efficacy of low-level laser therapy for body contouring and spot fat reduction. Obes Surg. 2011 Jun;21(6):722-9. doi: 10.1007/s11695-010-0126-y.
Avci P, Nyame TT, Gupta GK, Sadasivam M, Hamblin MR. Low-level laser therapy for fat layer reduction: a comprehensive review. Lasers Surg Med. 2013 Aug;45(6):349-57. doi: 10.1002/lsm.22153. Epub 2013 Jun 7.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical trial for LLLT in body contouring and fat reduction
510K clearance for body contouring, fat reduction, inflammation, and skin tightening. Ultraslim rebranded as Alesis OSA-1
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IORG0012434
Identifier Type: OTHER
Identifier Source: secondary_id
IORG0012434
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.